Skip to main content
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMLX ISIN · US0321085088 US Manufacturing
Open in API
Filings indexed 384 across all filing types
Latest filing 2022-10-07 Capital/Financing Update
Country US United States of America
Listing US AMLX

About Amylyx Pharmaceuticals, Inc.

https://www.amylyx.com/

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.

Recent filings

Filing Released Lang Actions
424B4
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(4) related to a public offering of common stock by Amylyx Pharmaceuticals, Inc. It includes information about the offering size, underwriting, risk factors, use of proceeds, dividend policy, capitalization, dilution, business overview, principal stockholders, and legal matters. The document is a registration and offering prospectus, which is a capital markets document related to financing activities. It is not an annual report, earnings release, or any other type of financial or governance report. The presence of underwriting details, offering price, and share issuance clearly indicates this is a Capital/Financing Update filing.
2022-10-07 English
Regulatory Filings 2022
Regulatory Filings
2022-10-07 English
S-1MEF
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes details about the registrant, offering, and exhibits such as legal opinions and consents. This type of filing is related to capital raising activities and financing. It is not an annual or quarterly report, audit report, or any other type of report listed. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual registration statement, not just an announcement or a certification.
2022-10-07 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter from underwriters to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references securities distribution and compliance with SEC rules. The document is short (2673 characters) and is a formal request related to a registration statement, not a financial report or earnings release. It does not contain financial data or detailed report content. This type of document is best classified as a Regulatory Filing (RNS), as it is a regulatory communication that does not fit into other specific categories like Capital/Financing Update or Share Issue/Capital Change, which would involve announcements of actual transactions or capital changes rather than procedural requests to the SEC.
2022-10-04 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and is signed by company executives. The content is a formal request related to the registration process for securities, not a financial report or earnings release. The document length is short (2189 characters) and it is a procedural communication rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-10-04 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used by companies to register securities for public offering under the Securities Act of 1933. It includes detailed information about the company, the offering, risk factors, use of proceeds, business overview, and other disclosures typical of an IPO or secondary offering registration statement. This is not an annual report, earnings release, or any other financial report but a capital markets filing related to fundraising and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full registration statement, not a brief announcement or a report publication announcement.
2022-10-04 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.